endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.62751/2713-0177-2025-6-2-07endofocus-152Research ArticleОБЗОР ЛИТЕРАТУРЫLITERATURE REVIEWРоль интенсивного контроля артериального давления при сахарном диабетеThe role of intensive blood pressure control in diabetes mellitushttps://orcid.org/0009-0003-4222-8695ПантелееваС. В.PanteleevaS. V.

Пантелеева Софья Викторовна – ординатор 2 года кафедры эндокринологии ИКМ

г. Москва

Sofia V. Panteleeva – 2nd year clinical resident of the Department of endocrinology, Institute of Clinical Medicine

Moscow

sofia7652809@mail.ruhttps://orcid.org/0000-0002-1385-0245ИзмайловаМ. Я.IzmailovaM. Ya.

Измайлова Марьям Ярагиевна – ассистент кафедры эндокринологии ИКМ

г. Москва

Maryam Ya. Izmailova – assistant at the Department of endocrinology

Moscow

aremizm@gmail.comФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииPirogov Russian National Research Medical University20252506202562Кардиоэндокринология58–63Copyright © Пантелеева С.В., Измайлова М.Я., 20252025Пантелеева С.В., Измайлова М.Я.Panteleeva S.V., Izmailova M.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/152

Артериальная гипертензия (АГ) – одно из наиболее распространенных сопутствующих заболеваний у пациентов с сахарным диабетом (СД), существенно увеличивающих риск неблагоприятного исхода и сердечно-сосудистых осложнений. Сочетание этих нозологий обусловлено наличием общих патогенетических механизмов метаболических расстройств, а также наследственных и приобретенных факторов. Частое сосуществование АГ и СД требует соблюдения определенных принципов ведения пациентов, направленных на многофакторный подход к управлению этими заболеваниями. Контроль артериального давления (АД), наряду с контролем уровня гликемии и показателей липидного профиля, служит одним из важнейших компонентов комплексной терапии СД и его осложнений. Вопросы о том, при каких значениях АД необходимо инициировать антигипертензивную терапию и какими должны быть целевые показатели АД у пациентов с диабетом, остаются дискуссионными в течение многих лет. Другим аспектом, требующим внимания, является ведение пациентов с СД, имеющих так называемую предгипертонию или высокое нормальное АД. В данной статье рассмотрены основные преимущества и риски интенсивного контроля АД у пациентов с СД, а также стратегии ведения пациентов с предгипертонией в соответствии с актуальными клиническими рекомендациями и последними данными клинических исследований.

Arterial hypertension (AH) is one of the most common comorbidities in patients with diabetes mellitus (DM), significantly increasing the risk of adverse outcomes and cardiovascular complications. The coexistence of these conditions is driven by shared pathophysiological mechanisms of metabolic disorders, as well as hereditary and acquired factors. Frequent coexistence of AH and DM requires certain principles of patient management and control. Blood pressure (BP) control, along with control of glycemia and lipid profile parameters, is one of the most important components of complex therapy of DM and its complications. The question of at what BP values it is necessary to initiate therapy and what should be the target BP values in patients with diabetes has been controversial for many years. Another issue requiring attention is the management of “prehypertension” or high normal BP in patients with DM. In this article, we will review the main benefits and risks of intensive BP control in patients with diabetes, as well as strategies for managing patients with prehypertension according to current clinical guidelines and the latest research data.

артериальная гипертензиясахарный диабетантигипертензивная терапияпредгипертонияarterial hypertensiondiabetes mellitusantihypertensive therapyprehypertensionReferencesWang Z, Yang T, Fu H. Prevalence of diabetes and hypertension and their interaction effects on cardio-cerebrovascular diseases: A cross-sectional study. BMC Public Health. 2021; 21(1): 1224. doi: 10.1186/s12889-021-11122-y.Wang Z, Yang T, Fu H. Prevalence of diabetes and hypertension and their interaction effects on cardio-cerebrovascular diseases: A cross-sectional study. BMC Public Health. 2021; 21(1): 1224. doi: 10.1186/s12889-021-11122-y.Кобалава Ж.Д., Конради А.О., Недогода С.В. с соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024; 29(9): 6117. doi: 10.15829/1560-4071-2024-6117.Кобалава Ж.Д., Конради А.О., Недогода С.В. с соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024; 29(9): 6117. doi: 10.15829/1560-4071-2024-6117.Kreutz R, Brunstrom M, Burnier M et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024; 126: 1–15. doi: 10.1016/j.ejim.2024.05.033.Kreutz R, Brunstrom M, Burnier M et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024; 126: 1–15. doi: 10.1016/j.ejim.2024.05.033.Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2018; 71(19): 2199–269. doi: 10.1016/j.jacc.2017.11.005.Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2018; 71(19): 2199–269. doi: 10.1016/j.jacc.2017.11.005.Muntner P, Carey RM, Gidding S et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. Circulation. 2018; 137(2): 109–18. doi:10.1161/CIRCULATIONAHA.117.032582.Muntner P, Carey RM, Gidding S et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. Circulation. 2018; 137(2): 109–18. doi:10.1161/CIRCULATIONAHA.117.032582.SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373(22): 2103–16. doi: 10.1056/NEJMoa1511939.SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373(22): 2103–16. doi: 10.1056/NEJMoa1511939.Jia G, Sowers JR. Hypertension in diabetes: An update of basic mechanisms and clinical disease. Hypertension. 2021; 78(5): 1197–205. doi: 10.1161/HYPERTENSIONAHA.121.17981.Jia G, Sowers JR. Hypertension in diabetes: An update of basic mechanisms and clinical disease. Hypertension. 2021; 78(5): 1197–205. doi: 10.1161/HYPERTENSIONAHA.121.17981.Sowers JR. Diabetes mellitus and vascular disease. Hypertension. 2013; 61(5): 943–47. doi: 10.1161/HYPERTENSIONAHA.111.00612.Sowers JR. Diabetes mellitus and vascular disease. Hypertension. 2013; 61(5): 943–47. doi: 10.1161/HYPERTENSIONAHA.111.00612.Hill MA, Yang Y, Zhang L et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021; 119: 154766. doi: 10.1016/j.metabol.2021.154766.Hill MA, Yang Y, Zhang L et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021; 119: 154766. doi: 10.1016/j.metabol.2021.154766.Whaley-Connell A, Sowers JR. Aldosterone and risk for insulin resistance. Hypertension. 2011; 58(6): 998–1000. doi: 10.1161/HYPERTENSIONAHA.111.182782.Whaley-Connell A, Sowers JR. Aldosterone and risk for insulin resistance. Hypertension. 2011; 58(6): 998–1000. doi: 10.1161/HYPERTENSIONAHA.111.182782.Zhou B, Carrillo-Larco RM, Danaei G et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304): 957–80. doi: 10.1016/S0140-6736(21)01330-1.Zhou B, Carrillo-Larco RM, Danaei G et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304): 957–80. doi: 10.1016/S0140-6736(21)01330-1.Бойцов С.А., Драпкина О.М., Шляхто Е.В. с соавт. Исследование ЭССЕ-РФ (Эпидемиология Сердечно-Сосудистых заболеваний и их факторов риска в регионах Российской Федерации). Десять лет спустя. Кардиоваскулярная терапия и профилактика. 2021; 20(5): 3007. doi: 10.15829/1728-8800-2021-3007.Бойцов С.А., Драпкина О.М., Шляхто Е.В. с соавт. Исследование ЭССЕ-РФ (Эпидемиология Сердечно-Сосудистых заболеваний и их факторов риска в регионах Российской Федерации). Десять лет спустя. Кардиоваскулярная терапия и профилактика. 2021; 20(5): 3007. doi: 10.15829/1728-8800-2021-3007.Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low dose aspirin in patient with hypertension: Principal results of the HOT randomized trial. Lancet 1998; 351(9118): 1755–62. doi: 10.1016/s0140-6736(98)04311-6.Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low dose aspirin in patient with hypertension: Principal results of the HOT randomized trial. Lancet 1998; 351(9118): 1755–62. doi: 10.1016/s0140-6736(98)04311-6.Rationale and design of the ADVANCE study: A randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in diabetes and vascular disease: PreterAx and DiamicroN modified-release controlled evaluation. J Hypertens Suppl. 2001; 19(4): S21–28.Rationale and design of the ADVANCE study: A randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in diabetes and vascular disease: PreterAx and DiamicroN modified-release controlled evaluation. J Hypertens Suppl. 2001; 19(4): S21–28.Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002; 61(3): 1086–97. doi: 10.1046/j.1523-1755.2002.00213.x.Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002; 61(3): 1086–97. doi: 10.1046/j.1523-1755.2002.00213.x.American Diabetes Association Professional Practice Committee. Introduction and methodology: Standards of Care in Diabetes-2024. Diabetes Care. 2024; 47(Supplement_1): S1–S4. doi: 10.2337/dc24-SINT.American Diabetes Association Professional Practice Committee. Introduction and methodology: Standards of Care in Diabetes-2024. Diabetes Care. 2024; 47(Supplement_1): S1–S4. doi: 10.2337/dc24-SINT.Bi Y, Li M, Liu Y et al.; BPROAD Research Group. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med. 2025; 392(12): 1155–67. doi: 10.1056/NEJMoa2412006.Bi Y, Li M, Liu Y et al.; BPROAD Research Group. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med. 2025; 392(12): 1155–67. doi: 10.1056/NEJMoa2412006.Vasan R, Larson M, Leip E et al. Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: A cohort study. Lancet. 2001; 358 (9594): 1682–86. doi: 10.1016/S0140-6736(01)06710-1.Vasan R, Larson M, Leip E et al. Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: A cohort study. Lancet. 2001; 358 (9594): 1682–86. doi: 10.1016/S0140-6736(01)06710-1.Cuspidi C, Facchetti R, Bombelli M et al. High normal blood pressure and left ventricular hypertrophy echocardiographic findings from the PAMELA population. Hypertension. 2019; 73(3): 612–19. doi: 10.1161/HYPERTENSIONAHA.118.12114.Cuspidi C, Facchetti R, Bombelli M et al. High normal blood pressure and left ventricular hypertrophy echocardiographic findings from the PAMELA population. Hypertension. 2019; 73(3): 612–19. doi: 10.1161/HYPERTENSIONAHA.118.12114.Nakai H, Takeuchi M, Nishikage T et al. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: Correlation with diabetic duration. Eur J Echocardiogr. 2009; 10(8): 926–32. doi: 10.1093/ejechocard/jep097.Nakai H, Takeuchi M, Nishikage T et al. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: Correlation with diabetic duration. Eur J Echocardiogr. 2009; 10(8): 926–32. doi: 10.1093/ejechocard/jep097.

The authors declare that there are no conflicts of interest present.